Guardant Health (GH - Free Report) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.
The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on July 30. On the other hand, if they miss, the stock may move lower.
While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.
Zacks Consensus EstimateThis provider of oncology testing services is expected to post quarterly loss of $0.40 per share in its upcoming report, which represents a year-over-year change of +9.1%.
Revenues are expected to be $316 million, up 36.2% from the year-ago quarter.
Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 0.52% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.
Price, Consensus and EPS Surprise
Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Guardant Health?For Guardant Health, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -4.48%.
On the other hand, the stock currently carries a Zacks Rank of #4.
So, this combination makes it difficult to conclusively predict that Guardant Health will beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Guardant Health would post a loss of$0.47 per share when it actually produced a loss of -$0.45, delivering a surprise of +4.26%.
Over the last four quarters, the company has beaten consensus EPS estimates three times.
Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Guardant Health doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Amova Asset Management Americas Inc. trimmed its position in shares of Guardant Health, Inc. (NASDAQ:GH – Free Report) by 24.5% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 483,557 shares of the company’s stock after selling 156,738 shares during the period. Amova Asset Management Americas Inc. owned 0.36% of Guardant Health worth $44,608,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in GH. Vanguard Group Inc. increased its stake in shares of Guardant Health by 2.1% during the 4th quarter. Vanguard Group Inc. now owns 12,160,768 shares of the company’s stock worth $1,242,101,000 after purchasing an additional 251,939 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in Guardant Health by 33.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,636,078 shares of the company’s stock valued at $575,670,000 after buying an additional 1,414,441 shares during the period. Franklin Resources Inc. raised its stake in Guardant Health by 14.9% in the fourth quarter. Franklin Resources Inc. now owns 3,361,547 shares of the company’s stock valued at $343,348,000 after buying an additional 435,232 shares during the period. Geode Capital Management LLC lifted its position in shares of Guardant Health by 9.4% in the fourth quarter. Geode Capital Management LLC now owns 3,213,657 shares of the company’s stock valued at $328,297,000 after buying an additional 277,001 shares during the last quarter. Finally, Fuller & Thaler Asset Management Inc. boosted its stake in shares of Guardant Health by 3.0% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 2,441,730 shares of the company’s stock worth $249,398,000 after acquiring an additional 72,162 shares during the period. 92.60% of the stock is owned by institutional investors.
Insider Activity In related news, Director Meghan V. Joyce sold 10,000 shares of the company’s stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $126.98, for a total value of $1,269,800.00. Following the transaction, the director directly owned 11,183 shares in the company, valued at approximately $1,420,017.34. This represents a 47.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helmy Eltoukhy sold 100,000 shares of the firm’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $126.30, for a total transaction of $12,630,000.00. Following the transaction, the chief executive officer directly owned 2,012,919 shares in the company, valued at approximately $254,231,669.70. This represents a 4.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 708,565 shares of company stock worth $90,556,597. Corporate insiders own 5.60% of the company’s stock.
Wall Street Analysts Forecast Growth A number of research analysts recently weighed in on the company. Guggenheim boosted their target price on Guardant Health from $160.00 to $190.00 and gave the stock a “buy” rating in a report on Thursday, July 16th. Wolfe Research assumed coverage on Guardant Health in a report on Tuesday, June 2nd. They set an “outperform” rating and a $150.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Guardant Health in a research report on Tuesday, April 21st. Piper Sandler set a $127.00 price objective on shares of Guardant Health in a report on Thursday, May 21st. Finally, Canaccord Genuity Group increased their price objective on shares of Guardant Health from $135.00 to $205.00 and gave the company a “buy” rating in a research report on Tuesday, July 14th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $160.04.
Read Our Latest Stock Analysis on Guardant Health
Guardant Health Trading Down 5.0% NASDAQ:GH opened at $148.07 on Tuesday. The stock has a 50 day simple moving average of $135.24 and a 200 day simple moving average of $110.66. The stock has a market cap of $19.63 billion, a P/E ratio of -43.68 and a beta of 1.59. Guardant Health, Inc. has a 1-year low of $40.35 and a 1-year high of $174.08.
About Guardant Health (Free Report)
Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.
The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.
See Also Five stocks we like better than Guardant Health The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GH – Free Report).
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEAmova Asset Management Americas Inc. Sells 1,207,787 Shares of DraftKings Inc. $DKNG
NEXT HEADLINE »Amova Asset Management Americas Inc. Cuts Stock Holdings in Rocket Lab Corporation $RKLB
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2026 after market close on Thursday, July 30, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com. The webcast will.
Information in Investor’s Business Daily is for informational and educational purposes only and should not be construed as an offer, recommendation, solicitation, or rating to buy or sell securities. The information has been obtained from sources we believe to be reliable, but we make no guarantee as to its accuracy, timeliness, or suitability, including with respect to information that appears in closed captioning. Historical investment performances are no indication or guarantee of future success or performance. Authors/presenters may own the stocks they discuss. We make no representations or warranties regarding the advisability of investing in any particular securities or utilizing any specific investment strategies. Information is subject to change without notice. For information on use of our services, please see our Terms of Use.
*Real-time prices by Nasdaq Last Sale. Real-time quote and/or trade prices are not sourced from all markets. Ownership data provided by LSEG and Estimate data provided by FactSet.
IBD, IBD Digital, IBD Live, IBD Weekly, Investor's Business Daily, Leaderboard, MarketDiem, MarketSurge and other marks are trademarks owned by Investor's Business Daily, LLC.
Not intended for distribution to U.S. newswire services or for dissemination in the U.S.
Red Deer, Alberta--(Newsfile Corp. - June 15, 2026) - Gamehost Inc. (TSX: GH) ("Gamehost") announced that the Court of King's Bench of Alberta has granted the final order authorizing Gamehost to proceed with its previously announced transaction with Pure Casino Entertainment Limited Partnership ("Pure") pursuant to which a subsidiary of Pure will acquire all of the outstanding common shares of Gamehost (the "Gamehost Shares") for $13.65 in cash per share (the "Transaction").
The Transaction was approved at a special meeting of the shareholders of Gamehost (the "Gamehost Shareholders") held on June 11, 2026. The Transaction will be implemented by way of a plan of arrangement under the Business Corporations Act (Alberta) and is expected to close in June 2026, subject to customary closing conditions, including regulatory approval under applicable gaming laws.
About Gamehost
Gamehost is a corporation incorporated under the laws of the Province of Alberta with its head office located in Red Deer, Alberta. Through its subsidiary, Gamehost Limited Partnership, Gamehost owns and operates: (i) the Great Northern Casino facility located in Grande Prairie, Alberta, (ii) the Rivers Casino and Entertainment Centre located in Fort McMurray, Alberta; (iii) the Deerfoot Inn & Casino facility located in Calgary, Alberta; (iv) the Service Plus Inns & Suites hotel located in Grande Prairie, Alberta, and (v) the Encore Suites by Service Plus extended stay hotel facility located in Grande Prairie, Alberta. It also owns an investment property located in Grande Prairie, Alberta adjacent to the Service Plus Inn. For more information, visit https://gamehost.ca.
About IGP and Pure
Indigenous Gaming Partners Inc. is a gaming company established in 2024 that is focused on developing a portfolio of high-quality, market-leading casinos through strategic acquisitions and operational excellence. The partnership is comprised of five institutional First Nations - Glooscap First Nation, Millbrook First Nation, Annapolis Valley First Nation, We'koqma'q L'nue'kati, and Paqtnkek Mi'kmaw Nation - along with Sonco Gaming Inc., an experienced Canadian casino management and development company. Through its operating entity, Pure Casino Entertainment Limited Partnership, IGP owns and operates Pure Casino Edmonton, Pure Casino Yellowhead, Pure Casino Calgary and Pure Casino Lethbridge, which collectively employ more than 1,200 people and welcome millions of guests each year. IGP represents a shared vision to build meaningful Indigenous ownership in Canada's entertainment industry while delivering high-quality gaming and hospitality experiences. IGP is dedicated to setting new standards in the gaming industry while fostering prosperity for its Indigenous communities, charitable partners, and provincial stakeholders. For more information, visit www.indigenousgamingpartners.ca.
Forward-Looking Information
This news release contains certain forward-looking information and forward-looking statements within the meaning of applicable Canadian securities laws (collectively, "forward-looking information"). Forward-looking information relates to future events or future performance and is based upon management's current internal expectations, estimates, projections, assumptions and beliefs. All information other than historical fact may be forward-looking information. Words such as "seek", "plan", "continue", "expect", "intend", "believe", "anticipate", "predict", "estimate", "may", "will", "could", "potential", and other similar words that indicate events or conditions may occur are intended to identify forward-looking information. In particular, this new release contains forward-looking information pertaining to the following: (i) the anticipated cash payments to Gamehost Shareholders should the Arrangement be completed and (ii) the anticipated timing of completion of the Transaction. This forward-looking information is based on certain expectations and assumptions, including that all conditions precedent to the completion of the Transaction are satisfied on terms acceptable to each of Gamehost and Pure, each acting reasonably, that there are not any material unexpected hurdles or delays in satisfying the remaining conditions precedent, that each of Gamehost and Pure honour their respective obligations under the Arrangement Agreement; and that Pure has the ability to satisfy its cash payment obligation at the closing of the Transaction. By its very nature, forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information. Gamehost believes the expectations reflected in the forward-looking statements contained in this news release are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this news release should not be unduly relied upon. Some of the risks that could cause results to differ materially from those expressed in the forward-looking information include: (i) the remaining conditions to the completion of the Arrangement may not be satisfied or waived; (ii) the timing of the completion of the Transaction may be changed or delayed; (iii) Pure may not have sufficient funds to pay the cash consideration on closing of the Transaction or, even if it has sufficient funds, may not pay the pay the cash consideration required to close the Transaction; (iv) the Arrangement Agreement may be terminated by either party under certain circumstances, including as a result of the occurrence of a material adverse change in respect of Gamehost; and (v) if the Transaction is not completed, Gamehost Shareholders will not receive the anticipated cash consideration per share. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking information contained in this news release is expressly qualified by this cautionary statement. These statements speak only as of the date of this news release. Except as required by law, Gamehost does not undertake any obligation to publicly update or revise any forward-looking information.
The TSX does not accept responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/301429
Source: Gamehost Inc.
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
Red Deer, Alberta--(Newsfile Corp. - June 12, 2026) - Gamehost Inc. (TSX: GH) ("Gamehost") announced that its shareholders (the "Gamehost Shareholders") have approved its previously announced transaction with Pure Casino Entertainment Limited Partnership ("Pure") pursuant to which a subsidiary of Pure will acquire all of the outstanding common shares of Gamehost (the "Gamehost Shares") for $13.65 in cash per share (the "Transaction").
The Transaction was approved at a special meeting of the Gamehost Shareholders held on June 11, 2026 (the "Meeting"). The Transaction required (i) the approval of 66 2/3% of the votes cast by the Gamehost Shareholders present or represented by proxy and entitled to vote at the Meeting and (ii) the approval of a simple majority of the votes cast by the Gamehost Shareholders present or represented by proxy and entitled to vote at the Meeting other than those persons required to be excluded from such vote for the purpose of Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions (the "Minority Shareholders"). At the Meeting, holders of 16,444,813 Gamehost Shares were present or represented by proxy, which represented 79.52% of the outstanding Gamehost Shares. Of the votes cast at the Meeting, the resolution approving the Transaction was approved by (i) 97.78% of the votes cast by the Gamehost Shareholders, and (ii) 97.35% of the votes cast by Minority Shareholders.
The Transaction will be implemented by way of a plan of arrangement under the Business Corporations Act (Alberta) and is expected to close in June 2026, subject to customary closing conditions, including the final approval of the Court of King's Bench of Alberta and regulatory approval under applicable gaming laws.
About Gamehost
Gamehost is a corporation incorporated under the laws of the Province of Alberta with its head office located in Red Deer, Alberta. Through its subsidiary, Gamehost Limited Partnership, Gamehost owns and operates: (i) the Great Northern Casino facility located in Grande Prairie, Alberta, (ii) the Rivers Casino and Entertainment Centre located in Fort McMurray, Alberta; (iii) the Deerfoot Inn & Casino facility located in Calgary, Alberta; (iv) the Service Plus Inns & Suites hotel located in Grande Prairie, Alberta, and (v) the Encore Suites by Service Plus extended stay hotel facility located in Grande Prairie, Alberta. It also owns an investment property located in Grande Prairie, Alberta adjacent to the Service Plus Inn. For more information, visit https://gamehost.ca.
About IGP and Pure
Indigenous Gaming Partners Inc. is a gaming company established in 2024 that is focused on developing a portfolio of high-quality, market-leading casinos through strategic acquisitions and operational excellence. The partnership is comprised of five institutional First Nations - Glooscap First Nation, Millbrook First Nation, Annapolis Valley First Nation, We'koqma'q L'nue'kati, and Paqtnkek Mi'kmaw Nation - along with Sonco Gaming Inc., an experienced Canadian casino management and development company. Through its operating entity, Pure Casino Entertainment Limited Partnership, IGP owns and operates Pure Casino Edmonton, Pure Casino Yellowhead, Pure Casino Calgary and Pure Casino Lethbridge, which collectively employ more than 1,200 people and welcome millions of guests each year. IGP represents a shared vision to build meaningful Indigenous ownership in Canada's entertainment industry while delivering high-quality gaming and hospitality experiences. IGP is dedicated to setting new standards in the gaming industry while fostering prosperity for its Indigenous communities, charitable partners, and provincial stakeholders. For more information, visit www.indigenousgamingpartners.ca.
Forward-Looking Information
This news release contains certain forward-looking information and forward-looking statements within the meaning of applicable Canadian securities laws (collectively, "forward-looking information"). Forward-looking information relates to future events or future performance and is based upon management's current internal expectations, estimates, projections, assumptions and beliefs. All information other than historical fact may be forward-looking information. Words such as "seek", "plan", "continue", "expect", "intend", "believe", "anticipate", "predict", "estimate", "may", "will", "could", "potential", and other similar words that indicate events or conditions may occur are intended to identify forward-looking information. In particular, this new release contains forward-looking information pertaining to the following: (i) the anticipated cash payments to Gamehost Shareholders should the Arrangement be completed and (ii) the anticipated timing of completion of the Transaction. This forward-looking information is based on certain expectations and assumptions, including that all conditions precedent to the completion of the Transaction are satisfied on terms acceptable to each of Gamehost and Pure, each acting reasonably, that there are not any material unexpected hurdles or delays in receiving the required approvals, that each of Gamehost and Pure honour their respective obligations under the Arrangement Agreement; and that Pure has the ability to satisfy its cash payment obligation at the closing of the Transaction. By its very nature, forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information. Gamehost believes the expectations reflected in the forward-looking statements contained in this news release are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this news release should not be unduly relied upon. Some of the risks that could cause results to differ materially from those expressed in the forward-looking information include: (i) the conditions to the completion of the Arrangement, including receipt of the required approval from the Court of King's Bench of Alberta and the required approvals under applicable gaming laws may not be satisfied or waived; (ii) the timing of the completion of the Transaction may be changed or delayed; (iii) Pure may not have sufficient funds to pay the cash consideration on closing of the Transaction or, even if it has sufficient funds, may not pay the pay the cash consideration required to close the Transaction; (iv) the Arrangement Agreement may be terminated by either party under certain circumstances, including as a result of the occurrence of a material adverse change in respect of Gamehost; and (v) if the Transaction is not completed, Gamehost Shareholders will not receive the anticipated cash consideration per share. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking information contained in this news release is expressly qualified by this cautionary statement. These statements speak only as of the date of this news release. Except as required by law, Gamehost does not undertake any obligation to publicly update or revise any forward-looking information.
The TSX does not accept responsibility for the adequacy or accuracy of this release.
Not intended for distribution to U.S. newswire services or for dissemination in the U.S.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/301309
Source: Gamehost Inc.
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the Guardant360® CDx liquid biopsy test as a companion diagnostic for VEPPANU (vepdegestrant). VEPPANU, jointly developed by Arvinas, Inc. and Pfizer Inc., is approved for the treatment of adults with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-), estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.
The approval of Guardant360 CDx enables a non-invasive, blood-based method to identify patients with ESR1 mutations who may be eligible for treatment with VEPPANU. ESR1 mutations are a known mechanism of resistance to endocrine therapy and are commonly observed in patients with advanced disease.
“This latest FDA approval using Guardant360 CDx reflects where cancer care is headed using blood-based testing to detect resistance earlier and guide smarter treatment decisions,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO. “By identifying ESR1 mutations with just a simple blood draw, we’re helping bring more precise, personalized options to patients when they need them most.”
Vepdegestrant, discovered by Arvinas and co-developed with Pfizer, is a PROteolysis TArgeting Chimera (PROTAC), a type of heterobifunctional protein degrader therapy. It is designed to selectively degrade the estrogen receptor, offering a targeted treatment option for patients whose cancers are driven by ESR1 mutations. The approval is supported by clinical data demonstrating the clinical utility of identifying ESR1 mutations to guide treatment selection in ER+/HER2- advanced breast cancer.
This latest FDA approval for Guardant360 CDx marks the third ESR1 companion diagnostic approval. It is the 26th companion diagnostic indication across multiple tumor types, building on the platform’s increasing clinical utility and broad coverage by Medicare and commercial payers, representing more than 300 million covered lives.
About Guardant360® CDx
Guardant360 CDx is the first FDA-approved liquid biopsy for comprehensive genomic profiling. It detects multiple genomic alterations across all solid tumors and is approved as a companion diagnostic for therapies in non-small cell lung cancer, breast cancer, and colorectal cancer. For more information, visit Guardant360 CDx.
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
Guardant Health Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2025 and in its other reports filed with or furnished to the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2026.
First Quarter 2026 Financial Highlights
For the three-month period ended March 31, 2026, as compared to the same period of 2025:
Reported total revenue of $301.7 million, an increase of 48%, driven by: Oncology revenue of $205.0 million, an increase of 36%, and approximately 86,000 oncology tests, an increase of 47% Biopharma & Data revenue of $53.0 million, an increase of 17% Screening revenue of $41.6 million, and approximately 44,000 Shield screening tests, compared to $5.7 million revenue and 9,000 tests in the prior year period Generated non-GAAP gross margin of 66%, compared to 65% for the first quarter of 2025 Recent Operating Highlights
Presented 38 abstracts at the 2026 American Association for Cancer Research Annual Meeting, highlighting the breadth and strength of the Guardant portfolio Enhanced Guardant360 Tissue capabilities with the addition of whole transcriptome profiling, expanding clinical utility Announced collaboration with Nuvalent to develop companion diagnostics in targeted cancer therapy with initial emphasis on Guardant360 Tissue Received FDA approval for Guardant360® CDx as a companion diagnostic for Arvinas and Pfizer’s VEPPANU for ER+/HER2- ESR1 mutated advanced breast cancer Leveraged InfinityAI real-world evidence to support the approval of Daiichi Sankyo’s ENHERTU Activated direct-to-consumer and influencer campaigns during Colorectal Cancer Awareness Month to drive awareness and demand Launched nationwide, multi-year collaboration with Quest to expand access to Shield and accelerate screening adoption Launched Shield Multi-Cancer Detection (MCD) in Asia through Manulife partnership “Our first-quarter revenue increased 48% year over year, reflecting strong momentum across the Guardant portfolio,” said Helmy Eltoukhy, co-founder and co-CEO. “Oncology testing volumes continued to accelerate, reaching 86,000 in the quarter, up 47% year over year. Guardant360 Liquid and Guardant360 Tissue demonstrated significant growth, and we saw strong receptivity to our expansion into therapy response monitoring with Guardant Reveal. We believe these trends, driven by our Smart platform and InfinityAI offerings, position us well for sustained growth and for extending our leadership in precision oncology.”
“We are pleased with our progress with Shield, including strong volume momentum exiting the first quarter,” said AmirAli Talasaz, co-founder and co-CEO. “We expect sustained volume growth as we further build out our commercial infrastructure and expand collaborations with Quest and other partners. With a disciplined focus on execution as we scale, we are well positioned to broaden our reach in cancer screening and drive long-term value creation.”
First Quarter 2026 Financial Results
Revenue was $301.7 million for the first quarter of 2026, a 48% increase from $203.5 million for the corresponding prior year period. Oncology revenue grew 36% to $205.0 million for the first quarter of 2026, from $150.6 million for the corresponding prior year period, primarily driven by an increase in Oncology test volume, which grew 47% over the prior year period, and an increase in reimbursement for our oncology tests. Screening revenue grew over 600% to $41.6 million for the first quarter of 2026, from $5.7 million for the corresponding prior year period, driven primarily by an increase in Shield screening test volume, which grew to approximately 44,000 tests in the first quarter of 2026, from approximately 9,000 tests in the prior year period. The increase was also attributable to an increase in reimbursement for our Shield screening tests. Biopharma and Data revenue grew 17% to $53.0 million for the first quarter of 2026, from $45.4 million for the corresponding prior year period. Licensing and other revenue was $2.1 million for the first quarter of 2026, compared to $1.9 million for the corresponding prior year period.
Gross profit, or total revenue less cost of revenue, was $196.7 million for the first quarter of 2026, an increase of $68.0 million or 53%, from $128.7 million for the corresponding prior year period. Gross margin, or gross profit divided by total revenue, was 65% for the first quarter of 2026, as compared to 63% for the corresponding prior year period.
Non-GAAP gross profit was $200.1 million for the first quarter of 2026, an increase of $68.8 million or 52%, from $131.3 million for the corresponding prior year period. Non-GAAP gross margin was 66% for the first quarter of 2026, as compared to 65% for the corresponding prior year period.
Operating expenses were $318.1 million for the first quarter of 2026, as compared to $239.8 million for the corresponding prior year period. Non-GAAP operating expenses were $268.1 million for the first quarter of 2026, as compared to $199.6 million for the corresponding prior year period. The year-over-year increase in both operating expenses and non-GAAP operating expenses was primarily related to commercial infrastructure expansion and marketing activities to support the Shield and Oncology growth.
Net loss was $112.1 million for the first quarter of 2026, as compared to $95.2 million for the corresponding prior year period. Net loss per share was $0.85 for the first quarter of 2026, as compared to $0.77 for the corresponding prior year period.
Non-GAAP net loss was $58.7 million for the first quarter of 2026, as compared to $61.1 million for the corresponding prior year period. Non-GAAP net loss per share was $0.45 for the first quarter of 2026, as compared to $0.49 for the corresponding prior year period.
Adjusted EBITDA loss was $58.9 million for the first quarter of 2026, as compared to a $58.5 million loss for the corresponding prior year period.
Free cash flow for the first quarter of 2026 was $(71.2) million, as compared to $(67.1) million for the corresponding prior year period.
Cash, cash equivalents, restricted cash and marketable securities were $1.2 billion as of March 31, 2026.
2026 Guidance
Guardant Health now expects full year 2026 revenue to be in the range of $1.30 to $1.32 billion, representing growth of 32% to 34% compared to full year 2025. This compares to the prior range of $1.25 to $1.28 billion, representing growth of 27% to 30%.
Within this revenue range:
Oncology revenue is now expected to grow in the range of 28% to 29% in 2026, compared to prior guidance of 25% to 27%. Oncology volume is now expected to grow greater than 35% in 2026, compared to prior guidance of approximately 30%. Guardant Health continues to expect Biopharma & Data revenue growth to be in the low double-digit range. Screening revenue is now expected to be in the range of $186 to $198 million, driven by Shield volume of 230,000 to 245,000 tests. This compares to the prior guidance of $162 to $174 million revenue and 210,000 to 225,000 tests. Guardant Health continues to expect full year 2026 non-GAAP gross margin to be in the range of 64% to 65%. Guardant Health now expects total non-GAAP operating expenses to be in the range of $1.05 to $1.07 billion, an increase compared to the prior range of $1.03 to $1.05 billion. Guardant Health continues to expect free cash flow burn to be in the range of $185 to $195 million, an improvement compared to $233 million for the full year 2025.
Webcast Information
Guardant Health will host a conference call to discuss the first quarter 2026 financial results after market close on Thursday, May 7, 2026 at 1:30 pm Pacific Time / 4:30 pm Eastern Time. A webcast of the conference call can be accessed at http://investors.guardanthealth.com. The webcast will be archived and available for replay for at least 90 days after the event.
Non-GAAP Measures
Guardant Health has presented in this release certain financial information in accordance with U.S. Generally Accepted Accounting Principles (GAAP) and also on a non-GAAP basis, including non-GAAP cost of revenue, non-GAAP gross profit, non-GAAP research and development expense, non-GAAP sales and marketing expense, non-GAAP general and administrative expense, non-GAAP loss from operations, non-GAAP net loss, non-GAAP net loss per share, basic and diluted, adjusted EBITDA, and free cash flow.
We define our non-GAAP measures as the applicable GAAP measure adjusted for the impacts of stock-based compensation and related employer payroll tax payments, contingent consideration, amortization of intangible assets, impairment of non-marketable equity securities, gain on extinguishment of convertible notes, and other non-recurring items.
Adjusted EBITDA is defined as net loss adjusted for interest income; interest expense; other income (expense), net; provision for income taxes; depreciation and amortization expense; stock-based compensation expense and related employer payroll tax payments; contingent consideration; and other non-recurring items. Free cash flow is defined as net cash used in operating activities in the period less purchases of property and equipment in the period.
We believe that the exclusion of certain income and expenses in calculating these non-GAAP financial measures can provide a useful measure for investors when comparing our period-to-period core operating results, and when comparing those same results to that published by our peers. We exclude certain items because we believe that these income and expenses do not reflect expected future operating performance. Additionally, certain items are inconsistent in amounts and frequency, making it difficult to perform a meaningful evaluation of our current or past operating performance. We use these non-GAAP financial measures to evaluate ongoing operations, for internal planning and forecasting purposes, and to manage our business.
These non-GAAP financial measures are not intended to be considered in isolation from, as substitute for, or as superior to, the corresponding financial measures prepared in accordance with GAAP. There are limitations inherent in non-GAAP financial measures because they exclude charges and credits that are required to be included in a GAAP presentation, and do not present the full measure of our recorded costs against its revenue. In addition, our definition of the non-GAAP financial measures may differ from non-GAAP measures used by other companies.
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2025, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.
Guardant Health, Inc.
Condensed Consolidated Statements of Operations
(unaudited)
(in thousands, except per share data)
Three Months Ended March 31,
2026
2025
Revenue
$
301,665
$
203,471
Costs and operating expenses:
Cost of revenue
104,919
74,723
Research and development expense
91,038
88,521
Sales and marketing expense
169,132
104,316
General and administrative expense
57,926
46,952
Total costs and operating expenses
423,015
314,512
Loss from operations
(121,350
)
(111,041
)
Interest income
11,151
9,112
Interest expense
(1,347
)
(791
)
Other income (expense), net
(157
)
7,851
Loss before provision for income taxes
(111,703
)
(94,869
)
Provision for income taxes
372
290
Net loss
$
(112,075
)
$
(95,159
)
Net loss per share, basic and diluted
$
(0.85
)
$
(0.77
)
Weighted-average shares used in computing net loss per share, basic and diluted
131,273
123,871
Guardant Health, Inc.
Condensed Consolidated Balance Sheets
(unaudited)
(in thousands, except share and per share data)
March 31, 2026
December 31, 2025
ASSETS
Current assets:
Cash and cash equivalents
$
989,291
$
378,203
Short-term marketable securities
113,469
823,395
Accounts receivable, net
137,404
137,849
Inventory, net
83,851
85,876
Prepaid expenses and other current assets, net
43,490
40,723
Total current assets
1,367,505
1,466,046
Restricted cash
112,150
111,214
Property and equipment, net
150,035
145,915
Right-of-use assets, net
153,906
158,849
Intangible assets, net
25,543
25,921
Goodwill
77,257
77,257
Other assets, net
28,895
28,457
Total Assets
$
1,915,291
$
2,013,659
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities:
Accounts payable
$
75,034
$
54,442
Accrued compensation
91,326
119,646
Accrued expenses
78,013
77,889
Deferred revenue
47,772
50,753
Total current liabilities
292,145
302,730
Convertible senior notes, net
1,503,471
1,504,000
Long-term operating lease liabilities
173,055
178,463
Other long-term liabilities
127,693
127,773
Total Liabilities
2,096,364
2,112,966
Stockholders’ deficit:
Common stock, par value of $0.00001 per share; 350,000,000 shares authorized; 131,514,404 and 130,635,301 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively
1
1
Additional paid-in capital
2,930,665
2,900,056
Accumulated other comprehensive loss
(5,152
)
(4,852
)
Accumulated deficit
(3,106,587
)
(2,994,512
)
Total Stockholders’ Deficit
(181,073
)
(99,307
)
Total Liabilities and Stockholders’ Deficit
$
1,915,291
$
2,013,659
Guardant Health, Inc.
Supplemental Revenue Information
(unaudited)
(in thousands)
Three Months Ended March 31,
2026
2025
Oncology
$
204,954
$
150,559
Biopharma and data
52,977
45,376
Screening
41,590
5,677
Licensing and other
2,144
1,859
Total revenue
$
301,665
$
203,471
Reconciliation of Selected GAAP Measures to Non-GAAP Measures
(unaudited)
(in thousands, except per share data)
Three Months Ended March 31,
2026
2025
GAAP cost of revenue
$
104,919
$
74,723
Amortization of intangible assets
(148
)
(148
)
Stock-based compensation expense and related employer payroll tax payments
(3,211
)
(2,390
)
Non-GAAP cost of revenue
$
101,560
$
72,185
GAAP gross profit
$
196,746
$
128,748
Amortization of intangible assets
148
148
Stock-based compensation expense and related employer payroll tax payments
3,211
2,390
Non-GAAP gross profit
$
200,105
$
131,286
GAAP research and development expense
$
91,038
$
88,521
Stock-based compensation expense and related employer payroll tax payments
(14,449
)
(13,090
)
Contingent consideration
—
(534
)
Non-GAAP research and development expense
$
76,589
$
74,897
GAAP sales and marketing expense
$
169,132
$
104,316
Stock-based compensation expense and related employer payroll tax payments
(14,702
)
(10,189
)
Non-GAAP sales and marketing expense
$
154,430
$
94,127
GAAP general and administrative expense
$
57,926
$
46,952
Amortization of intangible assets
(230
)
(332
)
Stock-based compensation expense and related employer payroll tax payments
(19,509
)
(13,571
)
Contingent consideration
—
(490
)
Other
(1,150
)
(2,000
)
Non-GAAP general and administrative expense
$
37,037
$
30,559
Three Months Ended March 31,
2026
2025
GAAP loss from operations
$
(121,350
)
$
(111,041
)
Amortization of intangible assets
378
480
Stock-based compensation expense and related employer payroll tax payments
51,871
39,240
Contingent consideration
—
1,024
Other
1,150
2,000
Non-GAAP loss from operations
$
(67,951
)
$
(68,297
)
GAAP net loss
$
(112,075
)
$
(95,159
)
Amortization of intangible assets
378
480
Stock-based compensation expense and related employer payroll tax payments
51,871
39,240
Contingent consideration
—
1,024
Impairment of non-marketable equity securities
—
5,000
Gain on extinguishment of convertible notes
—
(13,672
)
Other
1,150
2,000
Non-GAAP net loss
$
(58,676
)
$
(61,087
)
GAAP net loss per share, basic and diluted
$
(0.85
)
$
(0.77
)
Non-GAAP net loss per share, basic and diluted
$
(0.45
)
$
(0.49
)
Weighted-average shares used in computing GAAP and Non-GAAP net loss per share, basic and diluted
131,273
123,871
Reconciliation of GAAP Net Loss to Adjusted EBITDA
(unaudited)
(in thousands)
Three Months Ended March 31,
2026
2025
GAAP net loss
$
(112,075
)
$
(95,159
)
Interest income
(11,151
)
(9,112
)
Interest expense
1,347
791
Other expense (income), net
157
(7,851
)
Provision for income taxes
372
290
Depreciation and amortization
9,442
10,236
Stock-based compensation expense and related employer payroll tax payments
51,871
39,240
Contingent consideration
—
1,024
Other
1,150
2,000
Adjusted EBITDA
$
(58,887
)
$
(58,541
)
Reconciliation of Free Cash Flow to Net Cash Used in Operating Activities
Guardant Health (GH - Free Report) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to a loss of $0.49 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +4.60%. A quarter ago, it was expected that this provider of oncology testing services would post a loss of $0.42 per share when it actually produced a loss of $0.5, delivering a surprise of -19.05%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Guardant Health, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $301.67 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 8.31%. This compares to year-ago revenues of $203.47 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Guardant Health shares have lost about 9.7% since the beginning of the year versus the S&P 500's gain of 7.6%.
What's Next for Guardant Health?While Guardant Health has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Guardant Health was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.42 on $305.85 million in revenues for the coming quarter and -$1.50 on $1.27 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 40% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Lineage Cell (LCTX - Free Report) , is yet to report results for the quarter ended March 2026. The results are expected to be released on May 12.
This biotechnology company is expected to post quarterly loss of $0.02 per share in its upcoming report, which represents no change from the year-ago quarter. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Lineage Cell's revenues are expected to be $3.23 million, up 115.1% from the year-ago quarter.
While the top- and bottom-line numbers for Guardant Health (GH) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Guardant Health, Inc. delivered strong results in the first quarter, with accelerating revenue growth supported by the MRD and screening businesses. GH's Quest Diagnostics partnership, product upgrades, and expanded reimbursement are set to sustain strong fundamentals and revenue diversification. While Guardant's losses are still sizeable, the company is on a clear path to profitability, driven by the scaling on the MRD and screening businesses.
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on April 21, 2026, the Compensation Committee of Guardant's Board of Directors approved the granting of restricted stock units (“RSUs”) representing 143,898 shares of its common stock to 267 new non-executive employees with a grant date of May 11, 2026 under the Guardant Health, Inc. 2023 Employment Inducement Incentive Award Plan (the “Inducement Plan”). The RSUs w.
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® Liquid CDx, advancing blood-based comprehensive genomic testing by integrating genomic and epigenomic insights and helping clinicians make better-informed treatment selection decisions for patients with advanced cancer. Guardant360 Liquid CDx is the largest FDA-approved liquid biopsy panel, assess.
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardan
Guardant Health (GH) won Food and Drug Administration approval Wednesday for its newest cancer-analyzing blood test, sending the stock to a three-month high.
The approval comes several months ahead of expectations "and is likely to result in modest upward revenue revisions this year," William Blair analyst Andrew Brackmann said in a report.
↑ X NOW PLAYING Biotech's Next Boom? Inside The Multibillion Dollar Cancer Detection Market
The new test, dubbed Guardant360 Liquid CDx, has a 100 times wider genomic footprint than its predecessor, Guardant360 CDx. In both cases, these tests look for markers of cancer in a patient's blood. If the cancer exists, the tests examine the specific genomic and epigenomic drivers, helping direct treatment decisions.
"Beyond just this year, however, we view this as a major milestone that should begin to unlock long-term volume and test (average sales price) upside for the company's blood-based therapy selection business," Brackmann said. "These two levers (price and volume), in our view, should assist in total company revenue growth potentially accelerating in 2027."
Guardant Health stock surged 17.1%, ending the regular session at 114.97. Shares are forming a cup base with a buy point at 120.74.
A New Era In Cancer Care Cancer care is entering a new era, says Guardant Health Chief Executive Helmy Eltoukhy, "one where genomics, epigenomics, advanced AI, and learnings from more than 1 million patients tested converge to deliver a more complete, actionable view of cancer from just a blood draw."
Evercore ISI analyst Daniel Markowitz expects Guardant Health to seek Advanced Diagnostic Laboratory Test status under Medicare, which would allow the company to seek a premium price. He currently projects $5,000 per test increasing to around $8,000 with ADLT status.
He notes 2026 sales projections don't include the potential FDA approval of Guardant360 Liquid CDx. Analysts currently project $1.31 billion in sales this year and $1.68 billion for next, according to FactSet.
The Guardant360 franchise has grown by upper 20% to 30% range over the previous few quarters, William Blair's Brackmann said.
"If the higher Medicare reimbursement rate is secured by early next year as we anticipate, this should also result in the company becoming cash flow break-even during the year (versus the target of fourth quarter 2027)," he said.
Views On Guardant Health Stock Brackmann lists Guardant Health stock as a top pick for 2026. The next major milestone will be obtaining the ADLT designation, which could push 2027 revenue growth into the upper 30% range, from roughly 33% in 2025.
"As more investors appreciate these growth dynamics, at this revenue scale, we believe shares should move higher as the 2027 multiple appears more reasonable," he said.
He rates Guardant shares an outperform.
Evercore's Markowitz has a more moderate in-line rating on shares.
Follow Allison Gatlin on X/Twitter at @AGatlin_IBD.
YOU MAY ALSO LIKE:
How S&P Drug Titan Pfizer Plans To Outdo Its Own $6 Billion Franchise
Why These Two Biotech Stocks Just Rocketed, As One Prepares To Break Out
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
Follow Premarket And After-The-Open Action With IBD Experts
Learn How To Time The Market With IBD's ETF Market Strategy
The approval also transfers the seven previously approved companion diagnostic indications from Guardant360 CDx to the updated test.
The cancer testing company said Guardant360 Liquid CDx is now the largest FDA-approved liquid biopsy panel and evaluates a genomic footprint that is 100 times wider than the earlier Guardant360 CDx test.
The test combines genomic and epigenomic insights from a single blood sample to help clinicians make more informed treatment decisions.
New Platform Integrates Genomic And Epigenomic InsightsGuardant said the updated test is powered by its proprietary Smart Platform, an AI-enabled multiomic technology platform designed to improve circulating tumor DNA detection sensitivity compared with the previous Guardant360 CDx test.
According to the company, the platform integrates genomic and epigenomic profiling from one blood draw, helping identify clinically actionable information that may not be detected through genomics alone.
Faster Turnaround Time And Expanded Clinical UtilityGuardant said the updated liquid biopsy test can deliver results in as little as seven days. The company noted the test is designed to support treatment selection decisions regardless of tissue availability, therapy line, or practice setting.
The company also stated that Guardant360 Liquid CDx is the first liquid biopsy capable of simultaneously identifying genotype and key phenotype information.
Guardant added that its full oncology testing portfolio has now transitioned to the Smart Platform, which supports multiple cancer care applications across the treatment continuum using a single scalable testing infrastructure.
Price ActionGuardant Health shares were up 8.81% at $106.84 at the time of publication on Wednesday, according to Benzinga Pro.
Over the past month, GH has gained about 10.6% versus a 4.3% rise in the S&P 500 and is down roughly 2% year-to-date compared to the index’s 7.8% gain.
Photo by Tada Images via Shutterstock
Market News and Data brought to you by Benzinga APIs
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that its FDA-approved Shield™ blood test is now included in updated American Cancer Society (ACS) Colorectal Cancer (CRC) Screening Guidelines published today. The major screening guideline update recommends Shield as a choice for patients who decline or have not completed stool-based or visual examination screening tests. In an effort to address persistent screening gaps and.
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that its FDA-approved Shield⢠blood test is now included in updated Ameri
Founder's ClubSwingTraderLeaderboardMarketSurgeeIBDIBD DigitalIBD LiveCustomer Center
My Stock Lists
Email Preferences
Help & Support
Sign Out
Search stocks or keywords
Sections
My IBD
MARKET TREND
STOCK LISTS
STOCK RESEARCH
NEWSECONOMY
VIDEOS & PODCASTS
HOW TO INVESTEDUCATIONAL RESOURCESStoreMy Products
Founder's ClubSwingTraderLeaderboardMarketSurgeeIBDIBD DigitalIBD Live
Recently Searched
Travere Stock At 20-Year High, Leads 21 Newcomers To Best Stock Lists Like Big Cap 20
Stock Market Finds Rocket Fuel From Trump Canceling Iran Strikes; SpaceX Debut On Deck
Two AI Titans Flash Entries As Rocket Lab Readies For Launch Guardant Health (GH) stock spiked Wednesday after the American Cancer Society recommended its blood test as a screening tool for colon cancer. In the first update since 2021, the ACS added Guardant's Shield as a means of screening people ages 50 and older for colorectal cancer. Other screening methods include colonoscopies and Cologuard, a stool-based test from Exact Sciences. Abbott…
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present 38 abstracts, as well as one oral presentation in partnership with Pfizer, showcasing advances in methylation-based tumor classification and liquid biopsy technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois taking place May 29 – June 2, 2026.
Key data that will be presented include:
Abstract #3077 validating the use of Guardant360 Liquid CDx as a companion diagnostic for therapy selection and comprehensive pan-cancer tumor profiling in routine oncology practice. Findings led to recent FDA approval of the IVD assay, marking the world’s largest FDA-approved liquid biopsy panel, demonstrating how incorporating both genomic and epigenomic signals for variant detection produces strong analytical sensitivity, accuracy, and specificity across clinically relevant alterations. Abstract #3070 revealing the potential of Guardant360 Liquid in expanding access to targeted ALK inhibitor therapy and getting the right treatment to lung patients faster. Demonstrating advanced detection missed by standard genomic methods, the analysis demonstrated improved detection of actionable ALK fusions in non-small cell lung cancer (NSCLC) while maintaining high specificity by identifying additional ALK fusion-positive cases. Abstract #TPS10632 evaluating longitudinal performance of the Shield blood test for primary colorectal cancer screening in its intended use population, building off the strong performance in the prospective, observational ECLIPSE study that led to FDA approval. “Our presence at this year’s ASCO reflects the power of liquid biopsy tests to provide oncologists with actionable insights to more effectively treat patients in a faster amount of time,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO. “Guardant’s Smart Platform, an AI-enabled multiomic technology platform behind our next generation of cancer tests, is fueling the entire portfolio and supporting new clinical applications across the cancer care continuum.”
Key Guardant Health and collaborator presentations at ASCO 2026
Presentation
Title
Time / Location
8502
Lorlatinib vs crizotinib as first-line treatment for advanced ALK+ non-small cell lung cancer: 7-year update from the phase 3 CROWN study
May 29, 2026 / 1:00 - 4:00 PM CDT
3525 / 279
A deep learning approach to quantify tumor microenvironment features associated with postoperative ctDNA status and outcomes in a phase III FOLFOX-based adjuvant colon cancer trial (N0147; Alliance)
May 30, 2026 / 9:00 AM - 12:00 PM CDT
3546 / 313
A multicenter single-arm phase II trial evaluating the safety and efficacy of panitumumab and irinotecan in NeoRAS wild-type metastatic colorectal cancer patients (C-PROWESS)
May 30, 2026 / 9:00 AM - 12:00 PM CDT
3572 / 339
Circulating tumor DNA (ctDNA) tumor fraction (TF) dynamics to refine progression-free survival and radiographic response during anti-EGFR rechallenge in metastatic colorectal cancer
May 30, 2026 / 9:00 AM - 12:00 PM CDT
3659 / 426
Evaluation of circulating tumor DNA (ctDNA) burden, detected mutations and clinical outcomes in metastatic colorectal cancer (mCRC) using real-world data (RWD)
May 30, 2026 / 9:00 AM - 12:00 PM CDT
4050 / 33
Molecular circulating tumor DNA (ctDNA) profiling from patients (pts) treated with zanidatamab + chemotherapy (CT) in first-line (1L) HER2-positive (HER2+) advanced or metastatic gastroesophageal adenocarcinoma (mGEA)
May 30, 2026 / 9:00 AM - 12:00 PM CDT
4159 / 142
First-line GemCis ± immunotherapy vs FGFR inhibition in ctDNA-detected FGFR2 fusion-positive advanced cholangiocarcinoma: a real-world analysis
May 30, 2026 / 9:00 AM - 12:00 PM CDT
4161 / 144
Real-world analysis of epigenomic molecular tumor-type prediction for biliary tract cancer in CUP
May 30, 2026 / 9:00 AM - 12:00 PM CDT
4238 / 221
Real-world outcomes in gastrointestinal cancer patients with targetable genomic alterations identified on serial liquid biopsy
May 30, 2026 / 9:00 AM - 12:00 PM CDT
3051 / 188
Tumor-of-origin prediction using methylation signals from plasma cell-free DNA (cfDNA): Real-world experience in Asia and the Middle East (AME)
May 30, 2026 / 1:30 - 4:30 PM CDT
3052 / 189
Tissue-free minimal residual disease evaluation and clinical utility in early breast cancer: a real-world study
May 30, 2026 / 1:30 - 4:30 PM CDT
3070 / 207
Cell-free DNA methylation profile-based fusion epigenotyping to enhance ALK fusion detection in NSCLC patients
May 30, 2026 / 1:30 - 4:30 PM CDT
3077 / 214
Analytical validation of a plasma-based cfDNA NGS assay (Guardant360 Liquid CDx) for comprehensive solid tumor profiling
May 30, 2026 / 1:30 - 4:30 PM CDT
3105 / 242
Phase II basket trial of brigatinib for ALK fusion–positive solid tumors: ALLBREAK trial (WJOG15221M)
May 30, 2026 / 1:30 - 4:30 PM CDT
1031 / 145
Concordance between liquid and tissue biopsy in participants with newly diagnosed recurrent breast cancer
June 1, 2026 / 1:30 - 4:30 PM CDT
1095 / 209
Liquid-based methylation profiling of molecular breast cancer subtypes (MBS) in hormone receptor positive (HR+) metastatic breast cancer (MBC) treated with CDK4/6 inhibitor (CDK4/6i)
June 1, 2026 / 1:30 - 4:30 PM CDT
The full abstracts for Guardant Health and a list of all abstracts being presented at ASCO 2026 can be found on the ASCO website.
About Guardant360® Liquid CDx
The largest FDA-approved liquid biopsy, Guardant360 Liquid CDx is the only FDA-approved liquid biopsy test integrating genomic and epigenomic data for comprehensive insights. Guardant360 Liquid CDx is approved as a companion diagnostic for multiple therapies in non-small cell lung cancer and colorectal cancer. It is also the only FDA-approved companion diagnostic for targeted therapy in advanced breast cancer patients with ESR1 mutations. The test is broadly covered by Medicare and commercial insurers, representing over 300 million lives.
About Guardant360 Liquid
Guardant360 Liquid is a blood-based test that analyzes tumor DNA fragments circulating in the blood (cfDNA) to identify genetic mutations in advanced solid tumors, helping oncologists find targeted therapies. It offers an alternative to tissue biopsies, providing comprehensive genomic profiling (CGP) to guide personalized treatment for a wide range of solid cancers including lung, breast, colorectal, and prostate cancer. Guardant360 Liquid is guideline-complete across all advanced solid tumors, and has been clinically validated in more than 1,500 publications and research abstracts.
About Guardant Reveal
Guardant Reveal is a tissue-free liquid biopsy test that detects minimal residual disease (MRD) and monitors recurrence in early-stage colorectal, breast, and lung cancers, helping oncologists guide treatment decisions. In addition to MRD detection, Reveal can be used for late-stage therapy response monitoring for patients with solid tumors. Guardant Reveal therapy response monitoring can be initiated at any time during a patient’s treatment journey, offering clinicians flexibility and actionable insights.
The first clinical-validation study of pan-cancer chemotherapy monitoring published in The Journal of Liquid Biopsy showed that Guardant Reveal predicts long-term patient benefit up to 18 months earlier than standard clinical measures.
About Shield
Shield is a methylation partitioning cell-free DNA (mp-cfDNA) non-invasive, blood-based screening test that detects alterations associated with colorectal cancer in the blood. It is intended as a screening test for individuals at average risk for the disease, age 45 or older, and is not intended for individuals at high risk for colorectal cancer. The Shield test can be considered in a manner similar to guideline-recommended non-invasive CRC screening options and can be completed during any healthcare visit. A positive Shield result raises concern for the presence of colorectal cancer or advanced adenoma and the patient should be referred for colonoscopy evaluation.
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
Guardant Health Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2025 and in its other reports filed with or furnished to the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.
Colon cancer screening developer Guardant Health (GH) recently got powerful backing for one of its blood tests. As a result, shares popped and broke out of a base making it Thursday's IBD 50 Growth Stocks To Watch pick.
Guardant Health combines advanced blood and tissue tests and real-world data and artificial intelligence analytics to detect, monitor for recurrence and assist in treatment selection for cancer. The precision oncology company is not yet profitable, but its losses are dwindling and sales are rising.
↑ X NOW PLAYING Retatrutide Black Market: Why Consumers Will Do Anything To Get Eli Lilly's New GLP
The IBD 50 and IBD Leaderboard name has the first and only U.S. Food and Drug Administration approved blood test that screens for colorectal cancer. The test recently got the green light from the American Cancer Society and shares broke out of a cup base on the news.
On May 27, the American Cancer Society recommended Guardant's Shield blood test as another screening tool for colon cancer. It has sensitivity of 84% for colorectal cancer and a nearly 100% specificity for stage 2 cancer. Shield screens the blood for circulating tumor cells.
The blood test is intended for average-risk adults age 45 and older, and is an alternative to a stool sample test or a colonoscopy. The test strives to encourage adults who are in the 45 to 55 range and not getting tested, with an easy alternative method.
Another win for the company was an FDA approval on May 20 for its Guardant360 Liquid CDx blood test that looks for cancer markers.
The biotech also makes Guardant Health 360 liquid biopsy genomic test and offers a cancer test that combines genomic, epigenomic and RNA-based profiling.
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
Blood Test Stock Near A High Guardant stock jumped 6.4% following the Shield ACA news and bypassed a 120.74 buy point out of a first-stage cup base. This was its second attempt at breaking out. Shares were climbing nearly 3% Thursday and back near its all-time high of 133.97, reached on May 29. The biotech stock is now extended from the 5% buy zone reaching to 126.78, according to MarketSurge pattern recognition.
Its relative strength line has climbed sharply from late April lows.
The biotech stock's IBD Accumulation/Distribution Rating of A indicates heavy institutional buying over the last 13 weeks. And its 1.7 up/down volume ratio shows positive demand for the stock over the last 50 days.
Mutual funds own 74% of shares of Guardant stock, and have added shares for five straight quarters, according to IBD Stock Checkup. Moreover, seven IBD Mutual Fund Index names own Guardant, with the largest position of 1.54 million shares held by T. Rowe Price New Horizon Fund (PRNHX) in the March quarter.
Guardant Sees Jump In Colon Cancer Tests On May 7, Guardant Health reported its first-quarter sales rose 48% to $301.7 million, topping views. It performed 86,000 total cancer tests in the quarter, up 47% from a year ago. The company saw a quarterly loss of 85 cents per share vs. a loss of 77 cents per share in the same quarter of 2025.
It also raised its full-year 2026 revenue forecast to $1.3 billion to $1.32 billion — or growth of 32% to 34% — from its prior projection of between $1.25 billion and $1.28 billion. For 2027, Wall Street expects $1.7 billion sales.
Analysts call for a second-quarter loss of 75 cents per share, then smaller losses of 66 cents per share and 64 cents per share in the following two quarters.
Follow Kimberley Koenig for more stock market news on X, the platform formerly known as Twitter, @IBD_KKoenig.
YOU MAY ALSO LIKE:
Discover Profitable Trades Each Day With MarketDiem. See How.
What To Do When Growth Stocks Backtrack To Test Buy Points
Learn How To Time The Market With IBD's ETF Market Strategy
Looking For Market Insights? Check Out Our Live Daily Segment | Stocks To Watch
Blood-based liquid biopsy test enables identification of patients eligible for treatment with HERNEXEOS® (zongertinib tablets)
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® CDx as a companion diagnostic (CDx) for Boehringer Ingelheim’s HERNEXEOS® (zongertinib tablets), the first targeted therapy for adults with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC) as an initial treatment option.
The approval enables Guardant360 CDx, a liquid biopsy test that analyzes circulating tumor DNA (ctDNA) from a simple blood draw, to identify patients with HER2 (ERBB2) tyrosine kinase domain activating mutations who may be eligible for treatment with HERNEXEOS.
HERNEXEOS is indicated for the treatment of adult patients with unresectable or metastatic non-squamous NSCLC whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-authorized test. This indication was approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. More information and full prescribing information can be found at HERNEXEOS.com.
“This approval highlights the growing impact of liquid biopsy across advanced cancer care and underscores the utility of Guardant360 CDx to ensuring more patients can be matched to the right therapy at the right time,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO. “Guardant360 CDx has been at the forefront of enabling comprehensive genomic profiling through a simple blood draw, helping clinicians identify actionable mutations in genes such as HER2 with speed and accuracy.”
Guardant360 CDx was the first FDA-approved liquid biopsy that provides comprehensive genomic profiling across multiple tumor types and biomarkers. By detecting tumor-derived alterations in circulating cell-free DNA, the test helps clinicians match patients to appropriate targeted therapies and clinical trials.
“Companion diagnostics are essential to personalized lung cancer care, guiding biomarker-driven treatment decisions,” added Vicky Brown, U.S. Therapeutic Area Head for Oncology and Emerging Areas, Boehringer Ingelheim. “Guardant360 CDx will help identify patients with HER2-mutant advanced non-small cell lung cancer and connect eligible patients to the appropriate targeted therapy when timely treatment decisions matter most.”
NSCLC is the most common type of lung cancer, and a subset of patients harbor HER2 mutations that may be targetable with precision therapies. HER2-mutant NSCLC is an aggressive type of lung cancer that has been associated with a poor prognosis. Blood-based testing offers a faster, less invasive alternative to tissue biopsy, which can be challenging in advanced disease.
This latest FDA approval for Guardant360 CDx marks the 27th CDx indication across multiple tumor types globally, building on the platform’s increasing clinical utility and broad coverage by Medicare and commercial payers, representing more than 300 million covered lives.
For more information about Guardant360 CDx, visit www.guardanthealth.com.
About Guardant360® CDx
Guardant360 CDx is the first FDA-approved liquid biopsy for comprehensive genomic profiling. It detects multiple genomic alterations across all solid tumors and is approved as a companion diagnostic for therapies in non-small cell lung cancer, breast cancer, and colorectal cancer.
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
Guardant Health Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2025 and in its other reports filed with or furnished to the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.
